FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 358:676-688 February 14, 2008 Number 7 Next

	Full Text PDF PDA Full Text PowerPoint Slide Set Perspective by McFarland, H. F. Letters Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear PubMed Citation

ABSTRACT

Background There is increasing evidence that B lymphocytes are involved in the pathogenesis of multiple sclerosis, and they may be a therapeutic target. Rituximab, a monoclonal antibody, selectively targets and depletes CD20+ B lymphocytes.

Methods In a phase 2, double-blind, 48-week trial involving 104 patients with relapsing–remitting multiple sclerosis, we assigned 69 patients to receive 1000 mg of intravenous rituximab and 35 patients to receive placebo on days 1 and 15. The primary end point was the total count of gadolinium-enhancing lesions detected on magnetic resonance imaging scans of the brain at weeks 12, 16, 20, and 24. Clinical outcomes included safety, the proportion of patients who had relapses, and the annualized rate of relapse.

Results As compared with patients who received placebo, patients who received rituximab had reduced counts of total gadolinium-enhancing lesions at weeks 12, 16, 20, and 24 (P<0.001) and of total new gadolinium-enhancing lesions over the same period (P<0.001); these results were sustained for 48 weeks (P<0.001). As compared with patients in the placebo group, the proportion of patients in the rituximab group with relapses was significantly reduced at week 24 (14.5% vs. 34.3%, P=0.02) and week 48 (20.3% vs. 40.0%, P=0.04). More patients in the rituximab group than in the placebo group had adverse events within 24 hours after the first infusion, most of which were mild-to-moderate events; after the second infusion, the numbers of events were similar in the two groups.

Conclusions A single course of rituximab reduced inflammatory brain lesions and clinical relapses for 48 weeks. This trial was not designed to assess long-term safety or to detect uncommon adverse events. The data provide evidence of B-cell involvement in the pathophysiology of relapsing–remitting multiple sclerosis. (ClinicalTrials.gov number, NCT00097188 [ClinicalTrials.gov] .)

Source Information

From the Department of Neurology, University of California at San Francisco, San Francisco (S.L.H., E.W.); Montreal Neurological Institute, McGill University (D.L.A., J.A., A.B.-O.), and NeuroRx Research (D.L.A.) — both in Montreal; Barrow Neurology Clinics, Phoenix, AZ (T.V.); Mellen Center for Multiple Sclerosis, Cleveland Clinic, Cleveland (R.J.F.); Biogen Idec, Cambridge, MA (M.P.); and Genentech, South San Francisco, CA (N.S., S.A., A.L.-G., C.H.S.).

Address reprint requests to Dr. Hauser at the Department of Neurology, University of California at San Francisco, 505 Parnassus Ave., Box 0114, San Francisco, CA 94143-0114, or at hausers{at}neurology.ucsf.edu.

Full Text of this Article

Related Letters:

Rituximab in Relapsing–Remitting Multiple Sclerosis
Schrijver H. M., De Palma R., Sementa A., Chaudhuri A., Behan P. O., Hauser S. L., Waubant E., Bar-Or A., the HERMES Trial Group
Extract | Full Text | PDF  
N Engl J Med 2008; 358:2645-2647, Jun 12, 2008. Correspondence

This article has been cited by other articles:

• Helliwell, C. L., Coles, A. J. (2009). Monoclonal antibodies in multiple sclerosis treatment: current and future steps. Therapeutic Advances in Neurological Disorders 2: 195-203  
• Clatworthy, M. R., Watson, C. J.E., Plotnek, G., Bardsley, V., Chaudhry, A. N., Bradley, J. A., Smith, K. G.C. (2009). B-Cell-Depleting Induction Therapy and Acute Cellular Rejection. NEJM 360: 2683-2685 [Full Text]  
• Hutchinson, M (2009). Predicting and preventing the future: actively managing multiple sclerosis. PN 9: 133-143 [Abstract] [Full Text]  
• Carson, K. R., Evens, A. M., Richey, E. A., Habermann, T. M., Focosi, D., Seymour, J. F., Laubach, J., Bawn, S. D., Gordon, L. I., Winter, J. N., Furman, R. R., Vose, J. M., Zelenetz, A. D., Mamtani, R., Raisch, D. W., Dorshimer, G. W., Rosen, S. T., Muro, K., Gottardi-Littell, N. R., Talley, R. L., Sartor, O., Green, D., Major, E. O., Bennett, C. L. (2009). Progressive multifocal leukoencephalopathy after rituximab therapy in HIV-negative patients: a report of 57 cases from the Research on Adverse Drug Events and Reports project. Blood 113: 4834-4840 [Abstract] [Full Text]  
• Boster, A., Hreha, S., Berger, J. R., Bao, F., Penmesta, R., Tselis, A., Endress, C., Zak, I., Perumal, J., Caon, C., Vazquez, J., Tyler, K. L., Racke, M. K., Millis, S., Khan, O. (2009). Progressive Multifocal Leukoencephalopathy and Relapsing-Remitting Multiple Sclerosis: A Comparative Study. Arch Neurol 66: 593-599 [Abstract] [Full Text]  
• Christopeit, M., Schutte, V., Theurich, S., Weber, T., Grothe, W., Behre, G. (2009). Rituximab reduces the incidence of acute graft-versus-host disease. Blood 113: 3130-3131 [Full Text]  
• Wiendl, H., Hohlfeld, R. (2009). Multiple sclerosis therapeutics: Unexpected outcomes clouding undisputed successes. Neurology 72: 1008-1015 [Abstract] [Full Text]  
• Stuve, O., Leussink, V. I., Frohlich, R., Hemmer, B., Hartung, H.-P., Menge, T., Kieseier, B. C. (2009). Long-term B-Lymphocyte Depletion With Rituximab in Patients With Relapsing-Remitting Multiple Sclerosis. Arch Neurol 66: 259-261 [Abstract] [Full Text]  
• Coyle, P, Arnason, B, Hurwitz, B, Lublin, F (2009). Optimizing Outcomes in Multiple Sclerosis - A Consensus Initiative. Mult Scler 15: S5-S35 [Abstract]  
• Santer, D. M., Yoshio, T., Minota, S., Moller, T., Elkon, K. B. (2009). Potent Induction of IFN-{alpha} and Chemokines by Autoantibodies in the Cerebrospinal Fluid of Patients with Neuropsychiatric Lupus. J. Immunol. 182: 1192-1201 [Abstract] [Full Text]  
• Rohatagi, S., Zahir, H., Moberly, J. B., Truitt, K. E., Inaba, S.-i., Shimozato, T., Carrothers, T. J. (2009). Use of an Exposure-Response Model to Aid Early Drug Development of an Oral Sphingosine 1-Phosphate Receptor Modulator. J Clin Pharmacol 49: 50-62 [Abstract] [Full Text]  
• Furst, D E, Keystone, E C, Kirkham, B, Fleischmann, R, Mease, P, Breedveld, F C, Smolen, J S, Kalden, J R, Burmester, G R, Braun, J, Emery, P, Winthrop, K, Bresnihan, B, De Benedetti, F, Dorner, T, Gibofsky, A, Schiff, M H, Sieper, J, Singer, N, Van Riel, P L C M, Weinblatt, M E, Weisman, M H (2008). Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2008. Ann Rheum Dis 67: iii2-iii25 [Full Text]  
• Wekerle, H (2008). Lessons from multiple sclerosis: models, concepts, observations. Ann Rheum Dis 67: iii56-iii60 [Abstract] [Full Text]  
• Rieckmann, P., Traboulsee, A., Devonshire, V., Oger, J. (2008). Review: Escalating immunotherapy of multiple sclerosis. Therapeutic Advances in Neurological Disorders 1: 181-192 [Abstract]  
• Konig, F. B., Wildemann, B., Nessler, S., Zhou, D., Hemmer, B., Metz, I., Hartung, H.-P., Kieseier, B. C., Bruck, W. (2008). Persistence of Immunopathological and Radiological Traits in Multiple Sclerosis. Arch Neurol 65: 1527-1532 [Abstract] [Full Text]  
• The CAMMS223 Trial Investigators, (2008). Alemtuzumab vs. Interferon Beta-1a in Early Multiple Sclerosis. NEJM 359: 1786-1801 [Abstract] [Full Text]  
• Hauser, S. L. (2008). Multiple Lessons for Multiple Sclerosis. NEJM 359: 1838-1841 [Full Text]  
• Krumbholz, M., Meinl, I., Kumpfel, T., Hohlfeld, R., Meinl, E. (2008). Natalizumab disproportionately increases circulating pre-B and B cells in multiple sclerosis. Neurology 71: 1350-1354 [Abstract] [Full Text]  
• Borel, P., Benkhoucha, M., Weber, M. S., Zamvil, S. S., Santiago-Raber, M.-L., Lalive, P. H. (2008). Glatiramer acetate treatment does not modify the clinical course of (NZB x BXSB)F1 lupus murine model. Int Immunol 20: 1313-1319 [Abstract] [Full Text]  
• Harvey, B. P., Quan, T. E., Rudenga, B. J., Roman, R. M., Craft, J., Mamula, M. J. (2008). Editing Antigen Presentation: Antigen Transfer between Human B Lymphocytes and Macrophages Mediated by Class A Scavenger Receptors. J. Immunol. 181: 4043-4051 [Abstract] [Full Text]  
• Racke, M. K. (2008). Editorial: Challenges in developing new multiple sclerosis therapies. Therapeutic Advances in Neurological Disorders 1: 63-65  
• Novak, J. C., Lovett-Racke, A. E., Racke, M. K. (2008). Monoclonal Antibody Therapies and Neurologic Disorders. Arch Neurol 65: 1162-1165 [Abstract] [Full Text]  
• Centonze, D, Furlan, R, Gasperini, C, Salvetti, M, Battistini, L (2008). Early relapses after the first dose of natalizumab in active multiple sclerosis patients. Mult Scler 14: 1137-1138 [Abstract]  
• Linker, R. A., Kieseier, B. C. (2008). Review: Innovative monoclonal antibody therapies in multiple sclerosis. Therapeutic Advances in Neurological Disorders 1: 33-42 [Abstract]  
• Schrijver, H. M., De Palma, R., Sementa, A., Chaudhuri, A., Behan, P. O., Hauser, S. L., Waubant, E., Bar-Or, A., the HERMES Trial Group, (2008). Rituximab in Relapsing-Remitting Multiple Sclerosis. NEJM 358: 2645-2647 [Full Text]  
• Dalakas, M. C. (2008). Invited Article: Inhibition of B cell functions: Implications for neurology. Neurology 70: 2252-2260 [Abstract] [Full Text]  
• Krumbholz, M., Faber, H., Steinmeyer, F., Hoffmann, L.-A., Kumpfel, T., Pellkofer, H., Derfuss, T., Ionescu, C., Starck, M., Hafner, C., Hohlfeld, R., Meinl, E. (2008). Interferon-{beta} increases BAFF levels in multiple sclerosis: implications for B cell autoimmunity. Brain 131: 1455-1463 [Abstract] [Full Text]  
• (2008). B-Cell Depletion for MS. JWatch Neurology 2008: 1-1 [Full Text]